Rosivo — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rosivo is pioneering a decellularized and stabilized porcine cartilage implant platform to transform reconstructive surgery. The company's technology targets the substantial unmet need in rhinoplasty and facial reconstruction, where current graft options suffer from high long-term failure rates, leading to frequent revision surgeries. By offering a readily available, biocompatible, and mechanically stable product, Rosivo aims to make surgery safer, less invasive, and more predictable. Founded in 2019, the company is in the pre-clinical/development stage, building a team with expertise in biologics engineering and facial plastic surgery.

OphthalmologyFacial Plastic & Reconstructive Surgery

Technology Platform

Patented platform for creating decellularized, crosslinked, and sterilized biologic implants from porcine cartilage, designed to be stable, biocompatible, and resistant to resorption and warping.

Opportunities

The high revision rates in procedures like rhinoplasty, driven by graft failure, create a significant unmet need and a receptive market for a superior implant.

Rosivo's porcine-derived, off-the-shelf product could offer a cost-effective and logistically simpler alternative to cadaveric tissue, appealing to surgeons and hospitals.

Successful proof-of-concept could enable platform expansion into other large reconstructive surgery markets beyond facial procedures.

Risk Factors

The long-term in-vivo performance of the crosslinked porcine cartilage is unproven, carrying the risk of unforeseen resorption, immune reaction, or mechanical failure.

Navigating the FDA regulatory pathway for a novel biologic implant is a major hurdle that requires significant time and capital.

The company faces competition from established graft materials and new technologies, and must convince surgeons to adopt a new technique.

Competitive Landscape

Rosivo competes in the biologic implants space against human cadaveric tissue processors (e.g., LifeNet Health, MTF Biologics), synthetic implant manufacturers (e.g., Stryker, Medtronic), and other companies developing advanced biomaterials. Its key differentiator is the combination of a natural cartilage ECM with engineered stability, aiming to avoid the pitfalls of both existing biologic and synthetic options. Success depends on demonstrating clear clinical advantages in persistence and handling.

More companies in Regenerative Medicine →More companies in United States →